|
Search
Collections
Benchmarks
Upload document
Organization
Mastocytosis Center, Brigham and Women’s Hospital and Harvard Medical School
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
3 posters
Poster
HARBOR: A Phase 2/3 Study of BLU-263 in Patients With Indolent Systemic Mastocytosis and Monoclonal Mast Cell Activation Syndrome
Poster
A Phase 2/3 Study of BLU-263, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis (ISM) and Monoclonal Mast Cell Activation Syndrome (mMCAS)
Poster
A Phase 2/3 Study of BLU-263, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis (ISM) and Monoclonal Mast Cell Activation Syndrome (mMCAS)